Anticoagulation protocol reduces venous thromboembolisms in patients with traumatic brain injury

Recent reports suggest that prophylactic anticoagulation preventive anti-clotting medication can be safely used in patients with life-threatening TBI if the brain injury is stable.3

Information
Retrieved on: 
Thursday, March 26, 2020 - 4:00pm
Organisation: 
The Joint Commission
Geotags: 
, ,
Content
Key Points: 
  • Recent reports suggest that prophylactic anticoagulation preventive anti-clotting medication can be safely used in patients with life-threatening TBI if the brain injury is stable.3
    In the study, Implementation of a Prophylactic Anticoagulation Guideline for Patients with Traumatic Brain Injury , researchers at North Memorial Health Hospital, Robbinsdale, Minnesota, used a trauma registry to identify patients with TBI before and after implementation of a new prophylactic anticoagulation protocol that incorporates education, weekly audits and real-time adherence feedback.
  • A total of 681 patients with TBI were identified 368 pre-implementation (PRE) and 313 post-implementation (POST) of the VTE protocol.
  • Time to initiation for anticoagulation averaged 59 hours for POST patients compared to 140 hours for PRE patients.
  • The researchers concluded that the hospital-wide prophylactic anticoagulation protocol improved process measures and outcomes in patients with TBI.


Study in April 2020 issue of The Joint Commission Journal on Quality and Patient Safety

OAKBROOK TERRACE, Ill., March 26, 2020 (GLOBE NEWSWIRE) -- Traumatic brain injury (TBI) is one of the leading causes of death and disability worldwide.1 In the United States, approximately 2.8 million people sustain a TBI annually.2 A new study in the April issue of The Joint Commission Journal on Quality and Patient Safety details how a prophylactic anticoagulation protocol helped decrease venous thromboembolisms (VTEs) in patients with TBI.

Patients with TBI have an increased risk of developing complications from VTEs, a condition in which a blood clot forms and travels to the lungs, due to prolonged immobilization and a systemic hypercoagulability state. Recent reports suggest that prophylactic anticoagulation – preventive anti-clotting medication – can be safely used in patients with life-threatening TBI if the brain injury is stable.3

In the study, “Implementation of a Prophylactic Anticoagulation Guideline for Patients with Traumatic Brain Injury,” researchers at North Memorial Health Hospital, Robbinsdale, Minnesota, used a trauma registry to identify patients with TBI before and after implementation of a new prophylactic anticoagulation protocol that incorporates education, weekly audits and real-time adherence feedback.

A total of 681 patients with TBI were identified – 368 pre-implementation (PRE) and 313 post-implementation (POST) of the VTE protocol. Findings showed:

  • 80.5% of POST patients received anticoagulation compared to 39.4% of PRE patients.
  • Time to initiation for anticoagulation averaged 59 hours for POST patients compared to 140 hours for PRE patients.
  • POST patients (2.2%) had fewer VTE events compared to PRE patients (5.2%).   

The researchers concluded that the hospital-wide prophylactic anticoagulation protocol improved process measures and outcomes in patients with TBI. They also concluded that benchmarking can assist institutions to identify potential clinically relevant areas for quality improvement in real time.

“Quality improvement stories like the one described in this study provide blueprints for institutions to use their own benchmarked data to improve patient care. When appropriate decisions about using benchmarked data are combined with interventions tailored to the local context, the potential for application of benchmarked data to improve care at the bedside is high,” note Matthew C. Chia, MD, and Anthony D. Yang, MD, MS, in an accompanying editorial.

Also featured in the April issue:

For more information, visit The Joint Commission Journal on Quality and Patient Safety website

Note for editors
The article is “Implementation of a Prophylactic Anticoagulation Guidelines for Patients with Traumatic Brain Injury,” by Christopher J. Tignanelli, MD; Jonathan Gipson, MD, FACS; Arthur Nguyen, AB; Regina Martinez, BS, MPH; Simon Yang, BS, MS; Patty L. Reicks, RN, BSN; Cori Sybrant, BSN; Robert Roach, MD; Melissa Thorson, MS, APRN, CCNS; and Michaela A. West, MD, PhD, FACS. The article appears in The Joint Commission Journal on Quality and Patient Safety, volume 46, number 4 (April 2020), published by Elsevier.

The Joint Commission Journal on Quality and Patient Safety
The Joint Commission Journal on Quality and Patient Safety (JQPS) is a peer-reviewed journal providing health care professionals with innovative thinking, strategies and practices in improving quality and safety in health care. JQPS is the official journal of The Joint Commission and Joint Commission Resources, Inc. Original case studies, program or project reports, reports of new methodologies or the new application of methodologies, research studies, and commentaries on issues and practices are all considered.

1 Maas AI, Stocchetti N, Bullock R. Moderate and severe traumatic brain injury in adults. Lancet Neurol. 2008;7:728–741.

2 Taylor CA, et al. Traumatic brain injury–related emergency department visits, hospitalizations, and deaths—United States, 2007 and 2013. MMWR Surveill Summ. 2017 Mar 17;66:1–16.

3 Saadeh Y, et al. Chemical venous thromboembolic prophylaxis is safe and effective for patients with traumatic brain injury when started 24 hours after the absence of hemorrhage progression on head CT. J Trauma Acute Care Surg. 2012;73:426–430.

Media Contact:      
Katie Bronk
Corporate Communications
(630) 792-5175
kbronk@jointcommission.org

View the multimedia news release

Primary Logo